IP Library Granted Patent US 8,604,032
Granted Patent B2
US 8,604,032 · App. 13/112,611 · Granted Dec 10, 2013

Chemical compounds, compositions and methods for kinase modulation

Inventors: Pingda Ren (San Diego, CA); Yi Liu (San Diego, CA); Liansheng Li (San Diego, CA); Katrina Chan (San Diego, CA); Alfredo C. Castro (Winchester, MA); Catherine A. Evans (Somerville, MA)
Assignee: Infinity Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,604,032
App. No.
13/112,611
Granted
Dec 10, 2013
Kind
B2
Abstract

Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, and methods of use thereof The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.

Claims (59)

1. A compound of formula (Ib):

or a pharmaceutically acceptable salt thereof, wherein

B is hydrogen, or a moiety of Formula II:

wherein W c is 6-membered aryl or cycloalkyl;

q is an integer of 0, 1, 2, 3, or 4;

X is absent or —(CH(R 9 )) z —, and z is an integer of 1, 2, 3, or 4;

Y is absent, —O—, —S—, —S(═O)—, —C(═O)—, —C(═O)(CHR 9 ) z —, —N(R 9 )—, —N(R 9 )—C(═O)NH—, or —N(R 9 )C(R 9 ) 2 —, and z is an integer of 1, 2, 3, or 4;

R 1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amido, alkoxycarbonyl, sulfonamido, halo, cyano, or nitro;

each R 2 is independently alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, or carbonate;

R 3 is a 5-membered heteroaryl, a 5-membered nonaromatic heterocyclyl, a 6-membered heteroaryl, or a 6-membered nonaromatic heterocyclyl, each of which comprises at least one ring nitrogen, and each of which can be substituted with 0, 1, 2, or 3 R 13 ;

R 5 , R 6 , R 7 , and R 8 are independently hydrogen, halo, cyano, alkyl, or amino;

each R 9 is independently hydrogen, alkyl, or heterocycloalkyl;

W d is

R 11 is hydrogen, alkyl, halo, amino, amido, hydroxy, alkoxy, phosphate, urea, or carbonate;

R 12 is hydrogen, alkyl, haloalkyl, alkynyl, alkenyl, halo, —C(O)NH 2 , NH 2 , cyano, aryl, heteroaryl, nonaromatic heterocyclyl, or cycloalkyl;

R a is methyl;

R a′ is hydrogen, alkyl, —NH 2 , cyano, or halogen; and

each R 13 is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or halogen.

2. The compound of claim 1 , wherein R 3 is

3. The compound of claim 1 , wherein B is:

4. The compound of claim 3 , wherein q is 0 or 1.

5. The compound of claim 4 , wherein R 1 is hydrogen, alkyl, alkoxy, amido, halo, cyano, or nitro.

6. The compound of claim 4 , wherein q is 1 and R 2 is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, amino, halo, cyano, hydroxy or nitro.

7. The compound of claim 1 , wherein Y is —O—, —S(═O) 2 —, —C(═O)—, —N(R 9 )—, or —N(R 9 )—C(═O)—.

8. The compound of claim 1 , wherein X is —(CH(R9)) z —.

9. The compound of claim 8 , wherein z is 1, 2 or 3.

10. The compound of claim 8 , wherein R 9 is hydrogen or alkyl.

11. The compound of claim 1 , wherein W d is

12. The compound of claim 1 , wherein R 6 is hydrogen, halo, cyano or alkyl.

13. The compound of claim 1 , wherein R 7 is hydrogen, halo, cyano or alkyl.

14. The compound of claim 1 , wherein R 8 is hydrogen, halo, cyano or alkyl.

15. The compound of claim 2 , wherein B is:

16. The compound of claim 15 , wherein q is 0 or 1.

17. The compound of claim 16 , wherein R 1 is hydrogen, alkyl, alkoxy, amido, halo, cyano, or nitro.

18. The compound of claim 16 , wherein q is 1 and R 2 is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, amino, halo, cyano, hydroxy or nitro.

19. The compound of claim 2 , wherein Y is —O—, —S(═O) 2 —, —C(═O)—, or —N(R 9 )—.

20. The compound of claim 2 , wherein X is —(CH(R 9 )) z —.

21. The compound of claim 20 , wherein z is 1, 2 or 3.

22. The compound of claim 20 , wherein R 9 is hydrogen or alkyl.

23. The compound of claim 2 , wherein W d is

24. The compound of claim 2 , wherein R 6 is hydrogen, halo, cyano or alkyl.

25. The compound of claim 2 , wherein R 7 is hydrogen, halo, cyano or alkyl.

26. The compound of claim 2 , wherein R 8 is hydrogen, halo, cyano or alkyl.

27. The compound of claim 11 , wherein B is:

28. The compound of claim 27 , wherein q is 0 or 1.

29. The compound of claim 28 , wherein R 1 is hydrogen, alkyl, alkoxy, amido, halo, cyano, or nitro.

30. The compound of claim 28 , wherein q is 1 and R 2 is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, amino, halo, cyano, hydroxy or nitro.

31. The compound of claim 11 , wherein Y is —O—, —S(═O) 2 —, —C(═O)—, or —N(R 9 )—.

32. The compound of claim 11 , wherein X is —(CH(R 9 )) z —.

33. The compound of claim 32 , wherein z is 1, 2 or 3.

34. The compound of claim 32 , wherein R 9 is hydrogen or alkyl.

35. The compound of claim 11 , wherein R 6 is hydrogen, halo, cyano or alkyl.

36. The compound of claim 11 , wherein R 7 is hydrogen, halo, cyano or alkyl.

37. The compound of claim 11 , wherein R 8 is hydrogen, halo, cyano or alkyl.

38. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

39. The compound of claim 38 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

40. The compound of claim 38 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

41. The compound of claim 38 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

42. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable excipients.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2013
From: INTELLIKINE LLC
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 030590/0539 →
CHANGE OF NAME Recorded Aug 29, 2012
From: INTELLIKINE, INC.
To: INTELLIKINE LLC
Reel/Frame 028869/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: CASTRO, ALFREDO C.; EVANS, CATHERINE A.
To: INFINITY PHARMACEUTICALS, INC.
Reel/Frame 027562/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: REN, PINGDA; LIU, YI; LI, LIANSHENG; CHAN, KATRINA
To: INTELLIKINE, INC.
Reel/Frame 027562/0072 →
Continuity (2)
Provisional Application 61347370 · May 21, 2010
Related Publication 20120059000A1 · Mar 8, 2012